menu
    • menu
    [{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jaguar Gene Therapy

                            Israel arrow
                            EPS
                            Not Confirmed

                            Jaguar Gene Therapy

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAG201

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Gene Therapy to Start Pediatric Trial for ASD and Phelan-McDermid Syndrome

                            Details : JAG201 is an investigational gene replacement therapy for autism with SHANK3 mutations or deletions, administered via a one-time unilateral ICV injection, targeting the entire brain and spinal cord.

                            Product Name : JAG201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : JAG201

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jaguar Gene Therapy

                            Israel arrow
                            EPS
                            Not Confirmed

                            Jaguar Gene Therapy

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAG201

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Gene Therapy Clears IND for JAG201 in Autism Spectrum Disorder

                            Details : JAG201 is in preclinical studies for SHANK3-mutated autism and Phelan-McDermid syndrome, delivering SHANK3 via AAV9 vector.

                            Product Name : JAG201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 31, 2024

                            Lead Product(s) : JAG201

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Negev Autism Center Soroka University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciSparc to Commence its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

                            Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.

                            Product Name : SCI-210

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 14, 2023

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Negev Autism Center Soroka University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soro...

                            Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.

                            Product Name : SCI-210

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed

                            SciSparc

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disord...

                            Details : The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 (cannabidiol) in children and adolescents with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children...

                            Product Name : SCI-210

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 08, 2022

                            Lead Product(s) : Cannabidiol,Cannamide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ImmunoBrain Checkpoint

                            Israel arrow
                            EPS
                            Not Confirmed

                            ImmunoBrain Checkpoint

                            Israel arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBC-Ab002

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism S...

                            Details : The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.

                            Product Name : IBC-Ab002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 27, 2021

                            Lead Product(s) : IBC-Ab002

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institute on Aging

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth